IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd., MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion.
August 02, 2016
Share
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd. (KOSDAQ:A019550), MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion on July 27, 2016. The buyers will acquire 0.38 million shares at KRW 13000 per share.
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd. (KOSDAQ:A019550), MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. completed the acquisition of additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul on July 27, 2016.
Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd., MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion.
INVITES BIOCORE CO., LTD. 
